Loading...

PE anti-mouse CD25 Antibody

Pricing & Availability
Clone
PC61 (See other available formats)
Regulatory Status
RUO
Other Names
IL-2Rα, Ly-43, p55, Tac
Isotype
Rat IgG1, λ
Ave. Rating
Submit a Review
Product Citations
publications
PC61_PE_080607
Con A-stimulated (3 days) BALB/c mouse splenocytes stained with PC61 PE
  • PC61_PE_080607
    Con A-stimulated (3 days) BALB/c mouse splenocytes stained with PC61 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
102007 50 µg 55€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
102008 200 µg 181€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD25 is a 55 kD glycoprotein also known as the low affinity IL-2Rα, Ly-43, p55, or Tac. It is expressed on activated T and B cells, thymocyte subsets, pre-B cells, and T regulatory cells. In association with CD122 (IL-2Rβ) and CD132 (common γ chain), CD25 forms the high affinity signaling IL-2 receptor.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
IL-2-dependent cytolytic mouse T-cell clone B6.1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD25 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, in vitro blocking of IL-2 binding to low- and high-affinity receptors1-4, growth inhibition of IL-2-dependent T-cell lines1-4, in vivo depletion of CD25+CD4+ Treg cells5-8,10, and immunohistochemical staining of acetone-fixed frozen sections2. PC61 antibody recognizes a different epitope than 3C7 antibody (Cat. No. 101902). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 102040) with endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered. 

Application References
  1. Lowenthal JW, et al. 1985. Nature 315:669. (IP, Block)
  2. Ceredig R, et al. 1985. Nature 314:98. (IP, IHC, Block)
  3. Lowenthal JW, et al. 1985. J. Immunol. 135:3988. (Block)
  4. Moreau JL, et al. 1987. Eur. J. Immunol. 17:929. (Block)
  5. Takahashi T, et al. 2000. J. Exp. Med. 192:303. (Deplete)
  6. Onizuka S, et al. 1999. Cancer Res. 59:3128. (Deplete)
  7. Lei TC, et al. 2005. Blood 105:4865. (Deplete)
  8. Pasare C, et al. 2004. Immunity 21:733. (Deplete)
  9. León-Ponte M, et al. 2007. Blood 109:3139.
  10. Cao OW, et al. 2007. Blood doi:10.1182/blood-2007-02-073304. (Deplete)
  11. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719.
  12. Liu F, et al. 2011. Arch Toxicol. 85:1383. PubMed
  13. Anguela XM, et al. 2013. Diabetes. 62:551. PubMed
Product Citations
  1. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  2. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
  3. O'Malley G, et al. 2018. Cancer Immunol Res. 1.240277778. PubMed
  4. Elong Ngono A, et al. 2020. Cell Reports. 1.330555556. PubMed
  5. Merck E, et al. 2011. J Immunol. 187:110. PubMed
  6. Yu HH, et al. 2021. J Am Heart Assoc. 10:e023077. PubMed
  7. Hutter K, et al. 2022. Front Immunol. 13:967914. PubMed
  8. Nesseler JP, et al. 2020. Cancers (Basel). 12: . PubMed
  9. Wu R, et al. 2022. J Dermatol. 49:432. PubMed
  10. Koenig A, et al. 2022. Front Immunol. 12:791100. PubMed
  11. Liu H, et al. 2022. Cell Rep Med. 3:100660. PubMed
  12. Koutník J, et al. 2022. Front Immunol. 13:1049033. PubMed
  13. Lee JH, et al. 2023. Front Immunol. 13:1017132. PubMed
  14. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  15. Han S, et al. 2022. Cancer Immunol Res. 10:437. PubMed
  16. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  17. Schwarz A, et al. 2023. Front Immunol. 14:1038689. PubMed
  18. Giampaolo S, et al. 2023. iScience. 26:106234. PubMed
  19. Tong L, et al. 2023. Sci Adv. 9:eade5041. PubMed
  20. Wu J, et al. 2022. Nat Commun. 13:7321. PubMed
  21. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  22. Castiello MC, et al. 2020. J Allergy Clin Immunol. . PubMed
  23. Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed
  24. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  25. Ibrahim M, et al. 2016. J Evid Based Complementary Altern Med. 21: 171 - 176. PubMed
  26. Tyagi AM et al. 2018. Immunity. 49(6):1116-1131 . PubMed
  27. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  28. Imanishi T, et al. 2020. Cell Reports. 32(3):107911. PubMed
  29. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  30. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  31. Flaherty S, Reynolds J 2015. J Vis Exp. 98: 52739. PubMed
  32. Liu YJ, et al. 2020. Theranostics. 10:5225. PubMed
  33. Britton GJ et al. 2019. Immunity. 50(1):212-224 . PubMed
  34. Singh K, et al. 2015. Sci Rep. 14:7767. PubMed
  35. Feng H, et al. 2020. J Dermatol. 47:147. PubMed
  36. Holvoet B, et al. 2015. Stem Cell Reports. 5: 1183-1195. PubMed
  37. Xu L et al. 2017. Immunity. 47(3):538-551 . PubMed
  38. Freitas JT, et al. 2021. Pigment Cell Melanoma Res. 34:1084. PubMed
  39. Hutter K, et al. 2020. FEBS J. . PubMed
  40. Ma W, et al. 2017. Sci Rep. . 10.1038/s41598-017-15661-6. PubMed
  41. Diaz–Salazar C, et al. 2020. Cell Rep. 32:108186. PubMed
  42. Becher J, et al. 2018. Dev Cell. 47:592. PubMed
  43. Schoeler K, et al. 2019. FEBS J. 10.1111/febs.14934. PubMed
  44. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  45. White C, et al. 2015. J Immunol. 194:697. PubMed
  46. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  47. Li Z, et al. 2018. Front Immunol. 9:347. PubMed
  48. Chen Z, et al. 2021. Front Cell Dev Biol. 9:733308. PubMed
  49. Zhang Q, et al. 2022. Nat Commun. 13:2406. PubMed
  50. Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
  51. Su X, et al. 2022. J Transl Med. 20:378. PubMed
  52. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  53. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  54. Galle-Treger L, et al. 2016. Nat Commun. 7:13202. PubMed
  55. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  56. Kondo M, et al. 2016. J Immunol. 196: 563 - 572. PubMed
  57. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  58. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  59. Zhou J, et al. 2019. Nat Commun. 10:2427. PubMed
  60. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  61. Biton J, et al. 2016. J Immunol. 197: 1708 - 1719. PubMed
  62. Timilshina M, et al. 2017. PLoS One. 10.1371/journal.pone.0168942. PubMed
  63. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  64. Tong D, et al. 2020. Protein Cell. 0.533333333. PubMed
  65. Zhai X, et al. 2021. Sci Adv. 7:eabk0490. PubMed
  66. Gao X, et al. 2022. Front Immunol. 13:799331. PubMed
  67. Takenori Inomata, Jing Hua, Antonio Di Zazzo 2016. Sci Rep. 6:39924. PubMed
  68. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  69. Dahlgren MW et al. 2019. Immunity. 50(3):707-722 . PubMed
  70. Feng D, et al. 2022. Nat Commun. 13:5554. PubMed
  71. Yi H, et al. 2021. Front Immunol. 12:719189. PubMed
  72. Orlanski S, et al. 2016. Proc Natl Acad Sci U S A. 113: 5018-5023. PubMed
  73. Verma K, et al. 2017. PLoS One.. 10.1371/journal.pone.0183828. PubMed
  74. Schuler F, et al. 2017. Nat Commun. . 10.1038/s41467-017-01850-4. PubMed
  75. Draijer C, et al. 2018. Sci Rep. 8:5105. PubMed
  76. Tanaka Y, et al. 2017. J Immunol. 199:4016. PubMed
  77. Wen J, et al. 2020. Cell Rep. 31:107566. PubMed
  78. Wells AC et al. 2017. eLife. 6 pii: e26398. PubMed
  79. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  80. Xu JL, et al. 2022. Front Pharmacol. 13:911663. PubMed
  81. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  82. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  83. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  84. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  85. Wang X, et al. 2022. Elife. 11:. PubMed
  86. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  87. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  88. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  89. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  90. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  91. Hsieh WC, et al. 2018. Nat Commun. 9:463. PubMed
  92. Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed
  93. Chen YH, et al. 2022. Arthritis Res Ther. 24:27. PubMed
RRID
AB_312856 (BioLegend Cat. No. 102007)
AB_312856 (BioLegend Cat. No. 102008)

Antigen Details

Structure
Forms high affinity IL-2R with IL-2Rβ (CD122) and IL-2Rγ (CD132), 55 kD
Distribution

Activated T cells and B cells, thymocyte subset, pre-B cells, T regulatory cells

Function
IL-2 receptor
Ligand/Receptor
IL-2
Cell Type
B cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, Cytokine/Chemokine Receptors
Antigen References
  1. Taniguchi T, et al. 1993. Cell 73:5-8.
  2. Waldmann TA. 1991. J Biol Chem. 266:2681-4.
  3. Read S, et al. 2000. J Exp Med. 192:295-302.
  4. Lowenthal JW, et al. 1985. J Immunol. 135:3988-94.
Gene ID
16184 View all products for this Gene ID
UniProt
View information about CD25 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD25 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD25 PC61 FC
Biotin anti-mouse CD25 PC61 FC
FITC anti-mouse CD25 PC61 FC
PE anti-mouse CD25 PC61 FC
PE/Cyanine5 anti-mouse CD25 PC61 FC
Purified anti-mouse CD25 PC61 FC,IHC-F,IP,Block,Depletion
PE/Cyanine7 anti-mouse CD25 PC61 FC
Alexa Fluor® 488 anti-mouse CD25 PC61 FC
Alexa Fluor® 647 anti-mouse CD25 PC61 FC
Pacific Blue™ anti-mouse CD25 PC61 FC
Alexa Fluor® 700 anti-mouse CD25 PC61 FC
APC/Cyanine7 anti-mouse CD25 PC61 FC
PerCP/Cyanine5.5 anti-mouse CD25 PC61 FC
PerCP anti-mouse CD25 PC61 FC
Brilliant Violet 421™ anti-mouse CD25 PC61 FC
Brilliant Violet 605™ anti-mouse CD25 PC61 FC
Brilliant Violet 650™ anti-mouse CD25 PC61 FC
Ultra-LEAF™ Purified anti-mouse CD25 PC61 FC,IHC-F,IP,Block,Depletion
Brilliant Violet 510™ anti-mouse CD25 PC61 FC
PE/Dazzle™ 594 anti-mouse CD25 PC61 FC
Brilliant Violet 711™ anti-mouse CD25 PC61 FC
Brilliant Violet 785™ anti-mouse CD25 PC61 FC
Alexa Fluor® 594 anti-mouse CD25 PC61 IHC-F
APC/Fire™ 750 anti-mouse CD25 PC61 FC
TotalSeq™-A0097 anti-mouse CD25 PC61 PG
KIRAVIA Blue 520™ anti-mouse CD25 PC61 FC
TotalSeq™-B0097 anti-mouse CD25 PC61 PG
TotalSeq™-C0097 anti-mouse CD25 PC61 PG
Spark NIR™ 685 anti-mouse CD25 Antibody PC61 FC
PE/Fire™ 640 anti-mouse CD25 PC61 FC
Spark YG™ 581 anti-mouse CD25 PC61 FC
APC/Fire™ 810 anti-mouse CD25 PC61 FC
Brilliant Violet 750™ anti-mouse CD25 PC61 FC
PerCP/Fire™ 780 anti-mouse CD25 PC61 FC
PE/Fire™ 700 anti-mouse CD25 PC61 FC
Spark PLUS UV395™ anti-mouse CD25 PC61 FC
Spark Blue™ 574 anti-mouse CD25 (Flexi-Fluor™) PC61 FC
PerCP/Fire™ 806 anti-mouse CD25 Antibody PC61 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account